This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
June 6, 2013 /PRNewswire/ --
Bernstein Liebhard LLP today announced that it is investigating whether the Board of Directors of Impax Laboratories, Inc. (NASDAQ: IPXL) ("Impax" or the "Company"), in violation of its fiduciary duties, allowed Impax to be harmed by failing to maintain proper Good Manufacturing Practices at the Company's
Hayward, California facility during 2011 and 2013. In
March 2013, the U.S. Food and Drug Administration ("FDA"), after completing an inspection of the
Hayward facility, stated that it had found twelve problems in need of correction. The Company indicated that the manufacturing deficiencies noted by the FDA would delay Impax's launch of Rytary, an extended-release drug for treatment of Parkinson's disease.